A retrospective comparison of drugs against COVID-19
Retrospective 333 patients in China, with only 8 HCQ patients, showing shorter duration of hospitalization with HCQ.
hospitalization time, 35.2% lower, relative time 0.65, p = 0.04, treatment 8, control 277.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Tan et al., 14 Dec 2020, retrospective, China, peer-reviewed, 7 authors.
Abstract: Virus Research 294 (2021) 198262
Contents lists available at ScienceDirect
Virus Research
journal homepage: www.elsevier.com/locate/virusres
A retrospective comparison of drugs against COVID-19
Jiahong Tan 1, Yuan Yuan 1, Cheng Xu , Chunyan Song , Dan Liu , Ding Ma , Qinglei Gao *
Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, 430030, PR China
A R T I C L E I N F O
A B S T R A C T
Keywords:
Arbidol
Corticosteroids
Lopinavir/ritonavir
Hydroxychloroquine
Oseltamivir
COVID-19
Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a
comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a
total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oselta
mivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively
analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol
and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the
arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly
higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol,
lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the
potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination
therapy.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit